Evidence map›Paper›PMID 29847157›Full record

Trial reportJournal of child and adolescent psychopharmacology

Neurofunctional Correlates of Response to Quetiapine in Adolescents with Bipolar Depression.

Kiki Chang, Melissa DelBello, Amy Garrett, Ryan Kelley, Meghan Howe, Cal Adler, Jeffrey Welge, Stephen M Strakowski, Manpreet Singh

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kiki Chang1 Pediatric Bipolar Disorders Program, Stanford University School of Medicine , Stanford, California.
Melissa DelBello3 Division of Bipolar Disorders Research, University of Cincinnati School of Medicine , Cincinnati, Ohio.
Amy Garrett4 Health Science Center, The University of Texas , San Antonio, Texas.
Ryan Kelley1 Pediatric Bipolar Disorders Program, Stanford University School of Medicine , Stanford, California.
Meghan Howe1 Pediatric Bipolar Disorders Program, Stanford University School of Medicine , Stanford, California.
Cal Adler3 Division of Bipolar Disorders Research, University of Cincinnati School of Medicine , Cincinnati, Ohio.
Jeffrey Welge3 Division of Bipolar Disorders Research, University of Cincinnati School of Medicine , Cincinnati, Ohio.
Stephen M Strakowski5 Dell Medical School, The University of Texas , Austin, Texas.
Manpreet Singh1 Pediatric Bipolar Disorders Program, Stanford University School of Medicine , Stanford, California.
Menlo School · USThe University of Texas at Austin · USThe University of Texas Health Science Center at San Antonio · US

Funding

Genetic and Neurobiologic Risk Factors for Bipolar Disorder DevelopmentR01MH077047 · NIMH · STANFORD UNIVERSITY · PI CHANG, KIKI D · 2007 to 2011
$2.9M
NIMH NIH HHS R01 MH077047
6 · The paper itself

Abstract

objectivesPrior studies have shown that youth with bipolar disorder demonstrate neurofunctional changes in key prefrontal and subcortical brain regions implicated in emotional regulation following treatment with pharmacological agents. We recently reported a large response rate (>60%) to quetiapine (QUET) for treating depressive symptoms in adolescents with bipolar depression. This study investigates the neurofunctional effects of QUET using functional magnetic resonance imaging (fMRI).

methodsThirty-three unmedicated subjects, 10-17 years of age, with a current depressive episode (Children's Depression Rating Scale-Revised [CDRS-R] > 40) associated with bipolar I or II disorder were recruited in a two-site randomized, placebo (PBO)-controlled trial of QUET monotherapy for treatment of bipolar depression in adolescents. Twenty-three of these participants (nine male) underwent an MRI scan at baseline, then were randomized to QUET or PBO, followed for 8 weeks, and at the end of their study participation underwent another MRI scan. During the fMRI scan, subjects viewed negative and neutral pictures and rated the valence of each picture.

resultsSixteen subjects had usable data at both time points: 10 subjects randomized to QUET, and 6 randomized to PBO. For QUET subjects, lower baseline activation in the left dorsolateral prefrontal cortex (p < 0.005) and higher baseline activation in the left ventrolateral prefrontal cortex (p = 0.0024) predicted greater improvement in CDRS-R scores from baseline to follow-up. When QUET and PBO groups were combined (n = 16), region-of-interest activation did not significantly predict change in CDRS-R.

conclusionsBaseline activation patterns in dorsal and ventral portions of the prefrontal cortex that are critical for the regulation of emotion-predicted response, but only within the QUET group. Thus, specific medications may be more effective in the context of specific prefrontal activation patterns in youth with bipolar depression. Larger studies of these youth would help to clarify the effects of QUET on brain activation.

Indexed as

AdolescentAntidepressive AgentsBipolar DisorderBrainEmotionsFemaleHumansMagnetic Resonance ImagingMalePsychiatric Status Rating ScalesQuetiapine FumarateAntidepressive AgentsQuetiapine Fumarateadolescentsbipolar disordersfMRIquetiapine

Identifiers

PMID29847157
PMCPMC6065525
OpenAlexW2805633747

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.